Related Experiment Videos

Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile

G Lande1, S Demolombe, A Bammert

  • 1INSERM U533, Laboratoire de Physiopathologie et de Pharmacologie Cellulaires et Moléculaires G&R Laennec, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex 01, France.

Abstract

Insights

Transgenic mice overexpressing a dominant-negative KvLQT1 isoform effectively screen for drugs blocking the I(Kr) current. This model distinguishes I(Kr) blockers from those affecting other cardiac currents.

Area of Science:

  • Cardiology
  • Pharmacology
  • Genetics

Background:

  • Acquired long QT syndrome is frequently caused by drugs blocking the I(Kr) channel, impacting cardiac repolarization.
  • A transgenic (TG) mouse model overexpressing a dominant-negative KvLQT1 isoform was developed to evaluate drug effects in vivo.

Purpose of the Study:

  • To assess the utility of a TG mouse model for screening drugs that block the I(Kr) channel.
  • To differentiate I(Kr) blockers from drugs affecting other ion channels involved in cardiac repolarization.

Main Methods:

  • Transgenic (FVB) mice overexpressing a dominant-negative KvLQT1 isoform were used.
  • Six-lead ECGs were recorded in TG and wild-type (WT) mice after autonomic blockade.
  • Drug effects on corrected QT interval (QTrc) and sinus period were analyzed.

Main Results:

  • Specific I(Kr) blockers (dofetilide, E 4031, etc.) lengthened the sinus period in TG mice but not WT mice.
  • Tedisamil (transient outward current blocker) prolonged QTrc in WT mice but not TG mice.
  • Lidocaine and nicardipine showed distinct effects on QTrc and heart rhythm in both genotypes.

Conclusions:

  • KvLQT1-invalidated TG mice serve as a valuable in vivo model to distinguish I(Kr) blocking drugs.
  • This model can differentiate I(Kr) blockers from drugs targeting transient outward, sodium, or calcium currents.

Related Concept Videos